Nanwei Medical Technology Co., Ltd.

Short Form Report on Changes in Equity

Name of listed company: Nanwei Medical Technology Co., Ltd.

Stock listing place: Shanghai Stock Exchange

Stock abbreviation: South Micro Medicine.

Stock code: 688029

Information Disclosure Obligor: Huakang Limited

Residence: ROOM8107-08,81/F., INTERNATIONAL COMMERCE CENTRE,1

AUSTIN ROAD WEST, KOWLOON, HONG KONG

Address: ROOM8107-08,81/F., INTERNATIONALCOMMERCE

CENTRE,1AUSTIN ROAD WEST, KOWLOON, HONG KONG

Nature of changes in equity: share reduction; passive dilution due to the implementation of restricted stock incentive plans by listed companies; conversion of capital surplus to share capital by listed companies

Date of signature: February 20, 2023

Information Disclosure Obligor Statement

1. This report is prepared by the information disclosure obligor in accordance with the the People's Republic of China Securities Law, the Measures for the Administration of Acquisitions of Listed Companies, the Guidelines on the Content and Format of Information Disclosure by Companies Issuing Public Securities No. 15-Report on Changes in Equity and relevant laws, regulations and normative documents.

2. the information disclosure obligor has obtained the necessary authorization and approval for signing this report, its performance does not violate or conflict with any provisions in the articles of association or internal rules of the information disclosure obligor.

3. in accordance with the "the People's Republic of China Securities Law", "Administrative Measures for the Acquisition of Listed Companies" and "Guidelines for the Content and Format of Information Disclosure by Companies Offering Securities to the Public No. 15-Report on Changes in Equity", this report has fully disclosed the information disclosure obligors Changes in the shares of Nanwei Medical Technology Co., Ltd.

4. As of the date of this report, the Disclosure Obligor has not increased or decreased the shares in which it has an interest in Nanwei Medical Technology Co.

5. This change in equity is based on the information contained in this report. The information disclosure obligor has not entrusted or authorized any other person to provide information not listed in this report and make any explanation or explanation to this report.

The 6. Information Disclosure Obligor undertakes that there are no false records, misleading statements or material omissions in this report, and assumes legal responsibility for its truthfulness, accuracy and completeness.

7. some of the data in this report need to be rounded, so there may be differences in the mantissa, please note that investors.

Directory

Information Disclosure Obligor Statement ...... 2.

Section 1 Interpretation ...... 4

Section II Information Disclosure Obligor Introduction... 5.

Section III The purpose of this equity change and the shareholding plan... 6.

Section IV. Manner of this change in equity .... 7

Section V. Trading of shares of listed companies in the first six months ...... 9

Section VI Other Significant Matters ...... 10

Section VII Documents for Reference ...... 11

Section 8 Information Disclosure Obligor Statement ...... 12.

Schedule: Short Form Report on Changes in Equity .... 13

Section 1 Interpretation

In this report, unless otherwise stated, the following abbreviations have the following specific meanings:

This report refers to the "South Micro Medical Technology Co., Ltd. short-form equity change report."

book

South Micro Medical/Listed Company/Public Guide Micro Medical Technology Co., Ltd.

Division

Information Disclosure Obligor means Huakang Limited

/Huakang

Since the date of the Company's initial public offering and listing on the CRE Board

This equity change refers to the letter from (July 22, 2019) to February 20, 2023

The proportion of the company's shares held by the interest disclosure obligor decreased from 15.39 per cent

10.39 per cent, down 5 per cent

China Securities Regulatory Commission "China Securities Regulatory Commission"

Companies Act means the Companies Act of the People's Republic of China

Securities Act means the the People's Republic of China Securities Act.

Measures for the Administration of Acquisitions means the Measures for the Administration of Acquisitions of Listed Companies.

Standard No. 15 refers to the Guidelines on the Content and Format of Information Disclosure by Companies Issuing Public Securities.

No. 15-Report on Changes in Equity

SSE Shanghai Stock Exchange

Section II Information Disclosure Obligor Introduction.

Basic information of 1. information disclosure obligors

(I) the basic information of the information disclosure obligor

Name Huakang Limited

ROOM 8107-08,81/F.,INTERNATIONAL COMMERCE

Registered address CENTRE, 1 AUSTIN ROAD WEST, KOWLOON,HONG

KONG

Limited of major shareholder Evergreen Enterprises Holdings

Registered capital HK $1

Company Type Limited

Business scope Equity investment, asset management, not related to the issuer's main business.

Date of Establishment September 2, 2016

ROOM8107-08,81/F., INTERNATIONAL COMMERCE

Communication mode CENTRE,1 AUSTIN ROAD WEST, KOWLOON, HONG

KONG

Directors of (II) information disclosure obligors and their principal persons in charge

Name, position, gender, nationality, long-term residence, whether other countries have been acquired

or right of abode in the area

Zhang Junjie Director Male China Beijing No

Shen Qinhua Director Male China Zhejiang No.

The 2. disclosure obligor holds and controls more than 5% of the outstanding shares of other listed companies.

Condition

As of the date of this report, the Huakang does not hold or control more than 5% of the outstanding shares of other listed companies.

Section III The purpose of this equity change and the shareholding plan.

The purpose of this change in the rights and interests of the 1. information disclosure obligor.

The change in equity is influenced by a combination of factors such as the reduction of the shares of the listed company by the information disclosure obligor based on its own capital needs, the passive dilution of the shareholding ratio of the information disclosure obligor due to the implementation of the restricted stock incentive plan by the listed company, and the transfer of capital stock by the listed company.

The plan of the 2. information disclosure obligor to increase or reduce the shares of the listed company in the next 12 months.

The information disclosure obligor on January 30, 2023 through the listed company on the SSE website

(www.sse.com.cn) The Announcement on the Plan to Reduce Shares of Shareholders Holding More than 5% of Nanwei Medical Co., Ltd. (Announcement No. 2023-006) was disclosed. The information disclosure obligor plans to reduce the shareholding of the listed company by no more than 5,634,343 shares and no more than 3.00 per cent of the total share capital of the listed company through centralized bidding and block trading. Among them, those who intend to reduce their holdings through competitive bidding transactions shall not exceed 1,878,114 shares, that is, not more than 1.00 of the company's total share capital; those who intend to reduce their holdings through block transactions shall not exceed 3,756,229 shares, that is, not more than 2.00 of the company's total share capital. As of the date of this report, the Disclosure Obligor has no other plans to increase or reduce its holdings other than the above-mentioned reduction plan. After the end of the above-mentioned reduction plan, the information disclosure obligor will decide whether to further increase or reduce the shares of the listed company according to the overall situation of the securities market and other factors. In the event of relevant changes in rights and interests, the information disclosure obligor will perform relevant approval procedures and information in a timely manner in strict accordance with the requirements of relevant laws and regulations such as the Company Law, the Securities Law, the Measures for the Administration of Acquisitions, and Code No. 15. Disclosure obligations.

Section IV. Manner of this change in equity

1. of the shares of the listed company held by the information disclosure obligor before the equity change

According to the Company's disclosure of the "Initial Public Offering of Shares on the CRE Board", the Company's shares were listed in 2019.

Since July 22, 2012, it has been listed on the SSE's board, and the information disclosure obligor holds 20,524,600 of the company's shares.

shares, accounting for 15.39 per cent of the company's total share capital.

2. this change in equity

On December 22, 2021, the Company implemented the 2020 Restricted Stock Incentive Plan to grant certain shares for the first time.

The first vesting period of the first vesting period and the completion of the registration of shares, the total share capital of the company increased from 133,340,000 shares to 133,747,220 shares. After the share capital change, the number of shares held by the information disclosure obligor has not changed, and the shareholding ratio has been reduced from 15.39 per cent to 15.35 per cent.

On June 10, 2022, the Company implemented the capitalization of capital reserves and completed share registration to implement

The total share capital on the date of registration of the equity distribution in 2021 shall be the base, and the capital reserve shall be paid to all shareholders for every 10 shares.

Transfer of 4 shares, a total increase of 53,498,888 shares, after the transfer of the company's total share capital increased from 133,747,220 shares

187,246,108 shares. The number of shares held by the disclosure obligor increased from 20,524,600 to 28,734,440 shares, with no change in the percentage of shares held.

During the period of this equity change, the information disclosure obligor also reduced its holdings of the company's shares through centralized bidding and block trading, the specific changes are as follows:

Change Method of Shareholder NameDate of change Type of shares Less number of shares Reduction ratio

(Unit)

August 26, 2022

Centralized Bidding Day -2023 2 RMB Common Stock 3,750,575 2.00

Month 20

Huakang

19 August 2022

Block Trading Day -2022 12 RMB Common 5,464,322 2.91

Month 29

Total /// 9,214,897 4.91 percent

Note: In the above-mentioned reduction process, the Company implemented the 2020 Restricted Stock Incentive Plan for the first time to grant some shares of the second vesting period, the first vesting period reserved for the grant of incentive objects, and in 2022 12.

The registration of shares was completed on 29 January, and the total share capital of the company was increased from 187,246,108 shares to 187,811,442 shares. This

After the change in the share capital, the number of shares held by the information disclosure obligor has not changed and the shareholding ratio has been passively reduced. The reduction ratios mentioned in the table above are calculated using the Company's total share capital of 187,811,442 shares as of the date of this report.

Restricted rights of 3. disclosure obligors to have equity shares in listed companies

As of the date of this report, there is no restriction or restriction on the transfer of any rights such as pledge, seizure or freezing of the shares involved in this change of interest of the Information Disclosure Obligor.

Section V. Trading of shares of listed companies in the first six months

As of the six months prior to the date of signing of this report, the information disclosure obligor through the stock exchange centralized delivery.

Easy to buy and sell the shares of listed companies as follows:

Transaction Price

Number of shares traded between shareholders and counterparties.

Transaction Mode Percentage of total equity during the transaction period

To (shares)

(Yuan/share)

January 2023

Sell centralized bidding 21 to 2023 85.15-

Huakang 87.47 5,653 0.0030%

20 February

Centralized Bidding, December 2022

Huakang Sell 21 to 2023 74.11- 2,009,177 1.0698%

Block Trading 86.68

January 20

Centralized Bidding, November 2022

Huakang Sell 21 to 2022 72.93- 1,382,684 0.7362%

Block Trading 89.74

December 20th

October 2022

Huakang Sell Bulk Trade 21 to 2022 81.51- 1,135,022 0.6043%

89.81

20 November

Centralized bidding, September 2022

Huakang Sell 21 to 2022 62.00- 3,081,094 1.6405%

Block Trading 76.59

October 20

Centralized Bidding, August 2022

Sell 21 to 2022 69.01-

Huakang Block Trading 81.97 1,401,267 0.7461%

20 September

Section VI Other Major Matters

As of the date of signing this report, the information disclosure obligor has truthfully disclosed the relevant information of this equity change in accordance with relevant regulations, and there is no other information that must be disclosed in order to avoid misunderstanding of the content of the report, and China Other information that the Securities Regulatory Commission or the stock exchange requires disclosure but has not been disclosed in accordance with the law.

Section VII Documents for Reference

1. Documents for Reference

A copy of the registration certificate of the (I) information disclosure obligor;

The name list of the directors of the obligor of the (II) information disclosure and their principal responsible persons and the photocopies of their identification certificates;

The Short Form Report on Changes in Equity signed by the (III) Information Disclosure Obligor.

Location of 2. Documents for Reference

This report and the above-mentioned reference documents are placed in South Micro Medical Technology Co., Ltd. for inspection. Investors can also view the full text of this report on the SSE website (www.sse.com.cn).

Section 8 Statement of Information Disclosure Obligor

I (and the institution I represent) undertake that there are no false records, misleading statements or material omissions in this report, and I accept individual and joint legal responsibility for its truthfulness, accuracy and completeness.

Information Disclosure Obligor: Huakang Limited

Signature of Authorized Representative: Zhang Junjie, Shen Qinhua

Date of signature: February 20, 2023

Schedule: Short Form Report on Changes in Equity

Basic information

Name of the listed company Nanwei Medical Technology Co., Ltd. The location of the listed company is Nanjing, Jiangsu Province.

Stock abbreviation South Micro Medical Stock Code 688029.

ROOM 8107-08,81/F .,

Information Disclosure Obligor Information Disclosure Obligor Residence INTERNATIONAL

Name Huakang Limited COMMERCE CENTRE, 1

AUSTIN ROAD WEST

KOWLOON, HONG KONG

Increase in shares in which you have an interest □ Decrease √

No change in quantity, but change in shareholding ratio with or without concerted action with or without □ without √

□

Information Disclosure Obligor Yes □ No √ Information Disclosure Obligor Yes □ No √

Whether it is a listed company or not, it is actually a listed company.

The largest shareholder controller

Trading through centralized bidding on the stock exchange

Transfer by agreement □

Administrative transfer or change of state-owned shares □

Transfer by indirect means □

New shares issued by listed companies are acquired by means of changes in equity.

(Multiple choice allowed) Enforcement of court decision □

Inheritance □

Gift □

Other √ Passive dilution resulting from the implementation of restricted stock incentive plans by listed companies, the implementation of capital by listed companies

Capital reserve to increase share capital, block transactions.

Information Disclosure Obligor Stock Type: RMB Common Stock (A) Shares

Owned interest before disclosure

Number of shares and number of shares held: 20,524,600 shares held

Issued shareholding ratio of listed companies: 15.39 per cent

Share proportion

Type of shareholding: RMB ordinary shares (A)

BenNumber of shares held by sub-equity change: 19,519,543 shares held.

After that, the shareholding ratio of information disclosure: 10.39%

Number of changes in equity owned by the company: after the initial public offering of shares of the listed company and its listing on the SSE, in June 2022.

Number of shares and changes 10 days to implement capital reserve to increase share capital and complete share registration, the number of shares held by the information disclosure obligor increased.

Proportional 8,209,840 shares. Since then, the information disclosure obligor has cumulatively reduced its holdings of 9,214,897 shares through centralized bidding and block trading.

Proportion of change: 5.00%

Time in listed companies: December 22, 2021 to February 20, 2023

The mode of share change of equity: centralized bidding and block trading reduction, the time and method of movement caused by the implementation of the restricted stock incentive plan of the listed company, the implementation of the capital reserve of the listed company to increase the share capital.

Whether fully disclosed does not apply

Source of funds

Disclosure Obligor Yes □ No √

Is it planned for the next 12

Increase in holdings within months

Information Disclosure Obligor

The previous 6 months were

No buy in the secondary market Yes √ No □

Sell shares of the listed company

Tickets

If the controlling shareholder or actual controller of a listed company is involved in reducing its shareholding, the information disclosure obligor shall also explain the following:

controlling shareholder or actual

When the controller reduces its holdings, it is

No infringement listing does not apply

Corporate and shareholders' equity

The problem

controlling shareholder or actual

When the controller reduces its holdings, it is

Does there exist outstanding its

liabilities to the company,

The company has not been released for its inapplicability.

The burden provided by the liability

insurance, or damage to the public.

Other circumstances of the company's interests

shape

This change in equity is not applicable.

Whether approval is required

Is approved not applicable

(There is no text on this page, which is the signature page of the Schedule to the Short Form Equity Change Report of Nanwei Medical Technology Co., Ltd.)

Disclosure Obligor: Huakang Limited

Signature of Authorized Representative: Zhang Junjie and Shen Qinhua

Date of signature: 20 February 2023